摘要
A methodology drugs based on traditional to develop multi-component Chinese medicines has been developed using central composite design. Several active components from the traditional Chinese medicine turmeric were chosen for use in a multi-component antitumor drug. Response surface methodology based on a central composite design was applied to determine the quantitative composition-activity relationships in order to optimize the amount of each component in the drug. An MTT （3-（4,5- dimethylthiazol-2-yl）-2,5-diphenyltetrazolium bromide） assay was used to measure the pharmacological activity as the response value. The experimental antitumor activity of the optimum combination was 92.85% in the MTT assay and superior to the activities of each single component. These results demonstrate that response surface methodology based on a central composite design is suitable for the design of multi-component drugs.
A methodology drugs based on traditional to develop multi-component Chinese medicines has been developed using central composite design. Several active components from the traditional Chinese medicine turmeric were chosen for use in a multi-component antitumor drug. Response surface methodology based on a central composite design was applied to determine the quantitative composition-activity relationships in order to optimize the amount of each component in the drug. An MTT （3-（4,5- dimethylthiazol-2-yl）-2,5-diphenyltetrazolium bromide） assay was used to measure the pharmacological activity as the response value. The experimental antitumor activity of the optimum combination was 92.85% in the MTT assay and superior to the activities of each single component. These results demonstrate that response surface methodology based on a central composite design is suitable for the design of multi-component drugs.
